{"url":"https://lda.senate.gov/api/v1/filings/a38bfab7-4fcd-43fc-a007-2c872fcced2d/","filing_uuid":"a38bfab7-4fcd-43fc-a007-2c872fcced2d","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a38bfab7-4fcd-43fc-a007-2c872fcced2d/print/","filing_document_content_type":"text/html","income":null,"expenses":"970000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Samantha Ventimiglia","dt_posted":"2025-01-17T16:48:48-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"50 Northern Avenue","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Boston","registrant_state":"MA","registrant_zip":"02210","registrant":{"id":40027242,"url":"https://lda.senate.gov/api/v1/registrants/40027242/","house_registrant_id":39888,"name":"VERTEX PHARMACEUTICALS INCORPORATED","description":"Global biotechnology company","address_1":"50 Northern Avenue","address_2":null,"address_3":null,"address_4":null,"city":"Boston","state":"MA","state_display":"Massachusetts","zip":"02210","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SAMANTHA VENTIMIGLIA","contact_telephone":"+1 202-264-3511","dt_updated":"2026-07-29T12:53:27.346758-04:00"},"client":{"id":188223,"url":"https://lda.senate.gov/api/v1/clients/188223/","client_id":48,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-02-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144970,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144970,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Corporate tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}